ReviewProtein and peptide letters2025
Recombinant Proteins: Evolution to their Therapeutic Potential.
Review in Protein and peptide letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinant proteins, which are produced using recombinant DNA technology, have transformed the domains of biotechnology and biomedicine by allowing the production of proteins that are often expensive or difficult to obtain from natural sources. More than 130 recombinant proteins are currently in clinical use by the US FDA, demonstrating the importance of these proteins in both research and therapeutic applications. Bacterial, yeast, mammalian cell cultures, and hybridoma technology are examples of recombinant protein production systems that have enabled the large-scale production of therapeutic proteins, including monoclonal antibodies, which are now essential tools in disease treatment. From their origins with human insulin in the 1980s to the most recent developments in third-generation proteins, this brief review examines the development of recombinant protein therapies. The first generation concentrated on natural structures; the second generation focused on enhancing safety, pharmacokinetics, and specificity; and the third generation is ready to present innovative formulations and delivery systems. This review also covers the use of recombinant proteins in cancer treatment, different protein production systems, and design techniques that keep improving the safety and effectiveness profiles of protein therapies.
Indexed as
Identifiers
40760755What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.